These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 17289876

  • 1. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
    Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J.
    Clin Cancer Res; 2007 Feb 01; 13(3):844-50. PubMed ID: 17289876
    [Abstract] [Full Text] [Related]

  • 2. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Børresen AL, Cornelisse CJ, Devilee P.
    Cancer Res; 1994 Aug 01; 54(15):4200-6. PubMed ID: 8033152
    [Abstract] [Full Text] [Related]

  • 3. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors.
    Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y.
    Cancer Res; 2001 Sep 15; 61(18):6762-7. PubMed ID: 11559548
    [Abstract] [Full Text] [Related]

  • 4. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA, Zhuang Z, Man Y, Park WS, Emmert-Buck M, Tavassoli FA.
    Mod Pathol; 1999 Dec 15; 12(12):1083-9. PubMed ID: 10619258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL.
    Cancer Res; 2001 Mar 15; 61(6):2505-12. PubMed ID: 11289122
    [Abstract] [Full Text] [Related]

  • 11. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors.
    Soon PS, Libe R, Benn DE, Gill A, Shaw J, Sywak MS, Groussin L, Bertagna X, Gicquel C, Bertherat J, McDonald KL, Sidhu SB, Robinson BG.
    Ann Surg; 2008 Jan 15; 247(1):157-64. PubMed ID: 18156936
    [Abstract] [Full Text] [Related]

  • 12. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer.
    Roncuzzi L, Brognara I, Baiocchi D, Amadori D, Gasperi-Campani A.
    Oncol Rep; 2005 Aug 15; 14(2):471-4. PubMed ID: 16012732
    [Abstract] [Full Text] [Related]

  • 13. Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma.
    Suzuki K, Hirooka Y, Tsujitani S, Yamane Y, Ikeguchi M, Kaibara N.
    Anticancer Res; 2000 Aug 15; 20(2B):1257-62. PubMed ID: 10810431
    [Abstract] [Full Text] [Related]

  • 14. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A, Marzec B, Skomra D, Roessner A, Cybulski M, Rechberger T, Schneider-Stock R.
    Oncology; 2005 Aug 15; 69(4):317-25. PubMed ID: 16293976
    [Abstract] [Full Text] [Related]

  • 15. Alterations of the TP53 gene in human gliomas.
    Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH.
    Cancer Res; 1994 Mar 01; 54(5):1324-30. PubMed ID: 8118823
    [Abstract] [Full Text] [Related]

  • 16. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S, Poppe K, Fischer J, Nothnagel A, Estévez-Schwarz L, Haensch W, Schlag PM, Scherneck S.
    J Pathol; 2001 Jul 01; 194(3):318-26. PubMed ID: 11439364
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
    Beghelli S, Pelosi G, Zamboni G, Falconi M, Iacono C, Bordi C, Scarpa A.
    J Pathol; 1998 Sep 01; 186(1):41-50. PubMed ID: 9875139
    [Abstract] [Full Text] [Related]

  • 18. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
    Dahse R, Utting M, Werner W, Schimmel B, Claussen U, Junker K.
    Int J Oncol; 2002 Jan 01; 20(1):107-15. PubMed ID: 11743649
    [Abstract] [Full Text] [Related]

  • 19. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.
    Ott K, Vogelsang H, Mueller J, Becker K, Müller M, Fink U, Siewert JR, Höfler H, Keller G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2307-15. PubMed ID: 12796400
    [Abstract] [Full Text] [Related]

  • 20. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
    Obermann EC, Diss TC, Hamoudi RA, Munson P, Wilkins BS, Camozzi ML, Isaacson PG, Du MQ, Dogan A.
    J Pathol; 2004 Feb 01; 202(2):252-62. PubMed ID: 14743509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.